Resources from the same session
382O - Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring
Presenter: Jenny Seligmann
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Slides
Webcast
386O - Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)
Presenter: Salvatore Siena
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Slides
Webcast
LBA20 - FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO
Presenter: Chiara Cremolini
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Slides
Webcast
383O - MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)
Presenter: Filippo Pietrantonio
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 382O and 386O
Presenter: Pierre Laurent-Puig
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 1
Resources:
Slides
Webcast
Invited Discussant LBA20 and 383O
Presenter: Dominik Modest
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 1
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Dominik Modest
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 1
Resources:
Slides
Webcast